Journal profile · Multiple
Vaccine: X
ISSN 2590-1362 · Elsevier · United Kingdom
Vaccine: X: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.5 (journal website); fully open access; APC about USD 2,520; median 155 days to acceptance (34 articles, last 24 months); 158 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Vaccine: X is published by Elsevier and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Vaccine Coverage and Hesitancy, SARS-CoV-2 and COVID-19 Research and Influenza Virus Research Studies, together about 43.6% of its articles. Its main subfields are Epidemiology. (generated from OpenAlex topic counts and CAS ranking data)
Vaccine: X is the open access companion journal of Vaccine and has the same aims and scope. The journal offers authors who want to publish in a gold open access journal the opportunity to make their work immediately and permanently accessible.Vaccine: X publishes high quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas (such as passive immunization) are welcomed. Relevant, sound scientific work in all aspects of vaccine research that yielded negative results and would otherwise not be published is also welcome. Besides original research, we invite authors to submit basic science and clinical reviews, methodological articles, case reports, opinion and commentary pieces, visual pieces, and letters. Authors are required to consult the Guide for Authors as the submission guidelines are dynamic and therefore subject to change.
From the journal's Aims & Scope
Research area (LetPub): Multiple
Editor-in-chief Richard B. KennedyPublisher website
Editorial board by country: 1 in mainland China (about 3%); most named United States 11, Australia 5, Italy 4, United Kingdom 2, Netherlands 2 (33 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Vaccine Coverage and HesitancySocial Sciences23.4%
- SARS-CoV-2 and COVID-19 ResearchMedicine12.5%
- Influenza Virus Research StudiesMedicine7.6%
- Respiratory viral infections researchMedicine5.4%
- Immune responses and vaccinationsImmunology and Microbiology5.2%
- COVID-19 epidemiological studiesMathematics3.7%
- Cervical Cancer and HPV ResearchMedicine3.5%
- Virology and Viral DiseasesMedicine3.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 2.5Publisher website ·
- CiteScore 2026-06
- 4.2LetPub ·
- CiteScore (publisher)
- 4.2Publisher website ·
- SJR 2026-06
- 0.7LetPub ·
- SNIP 2026-06
- 0.73LetPub ·
- h-index
- 34OpenAlex ·
- i10-index
- 190OpenAlex ·
- 2-year mean citedness
- 2.5OpenAlex ·
- Self-citation rate
- 4%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 129LetPub ·
Articles by year OpenAlex count · 850 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 127 | 127 | 18 |
| 2025 | 158 | 158 | 162 |
| 2024 | 169 | 169 | 955 |
| 2023 | 163 | 163 | 1,197 |
| 2022 | 115 | 115 | 1,418 |
| 2021 | 50 | 50 | 923 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
155 daysMedian, submission to acceptance · P25–P75 110 days – 241 days
- Acceptance to online
- median 3 days (33 articles)
- Submission to online
- median 156 days
- Sample
- 34 articles with submission and acceptance dates (52 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 13 weeksLetPub ·
- Submission to first decision
- 7 daysPublisher website ·
- First decision after review
- 79 daysPublisher website ·
- Submission to acceptance
- 134 daysPublisher website ·
- Acceptance to publication
- 3 daysPublisher website ·
- Submission to publication (journal-reported)
- about 13 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,520 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,440 / EUR 2,280 / GBP 1,950 / JPY 302,630 | — | — | |
| LetPub | USD 2,000 | Yes | — | |
| Publisher website | USD 2,550 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
- Graphical abstract
- Optional
- Cover letter
- Required
Article types accepted17
- case reportVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…Length not stated
- case reportsVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Length not stated
- commentariesVaccine: X also welcomes thoughtful Opinion Pieces and Commentaries on topics of interest to the readership of the journal.Length not stated
- commentaryVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…Length not stated
- conference reportVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…Length not stated
- conference reportsVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Length not stated
- letterVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…Length not stated
- letters to the editorsVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Length not stated
- opinionVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…Length not stated
- opinion piecesVaccine: X also welcomes thoughtful Opinion Pieces and Commentaries on topics of interest to the readership of the journal.Length not stated
- research paperVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…Length not stated
- research papersVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Length not stated
- reviewVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…Length not stated
- review articleVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…Length not stated
- review articlesVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Length not stated
- short communicationVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…Length not stated
- short communicationsVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Data availability
Data statement required at submission Model summary
To foster transparency, you are required to state the availability of any data at submission.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed, does not count as prior publication Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2590-1362
- Society / sponsor
- Japanese Society for Vaccinology
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Vaccine: X
What CAS zone is Vaccine: X in?
In the 2025 upgraded edition of the CAS Journal Ranking, Vaccine: X is in Zone 4 of Medicine, and in Zone 4 of the minor category Immunology / Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Vaccine: X?
The journal's website gives an impact factor of 2.5; this is the journal's own figure, as LetPub lists none for it; CiteScore 4.2, h-index 34.
How long does peer review take at Vaccine: X?
Based on the dates recorded on 34 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 155 days (interquartile range 110–241 days); authors report an average review time of about 13 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Vaccine: X?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; Highlights: Optional; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Vaccine: X based?
Of the 33 board members whose country the journal's board page names, 1 (about 3%) are in mainland China; the countries named most often are United States (11), Australia (5) and Italy (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Vaccine: X?
According to LetPub and DOAJ records, Vaccine: X is indexed in ESCI, Scopus and DOAJ.
Is Vaccine: X open access, and what is the APC?
Vaccine: X is a fully open-access journal. APC about USD 2,520.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .